Although the exact sequels of stimulating 4-1BB action is not completely understood, boosting 4-1BB action by agonistic antibodies is considered as a promising strategy to anti-cancer immunotherapy (38) and should be considered in the treatment of melanoma as well. Here, TNFRSF9 is linked to melanoma.